This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

US FTC failed to meet its burden, Edwards, JenaValve argue in post-trial brief

( December 13, 2025, 00:18 GMT | Official Statement) -- MLex Summary: Edwards Lifesciences and JenaValve Technology submitted their post-trial brief and redacted proposed findings of fact and conclusions of law today, arguing that the US Federal Trade Commission failed to meet its burden that an injunction is in the public interest and that their transaction is of "paramount importance" to bring lifesaving treatment to patients. The defense maintains that the deal would save lives and increase innovation and that the government failed to show harm in any alleged market or that anticompetitive effects outweigh procompetitive effects.See document attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login